1. Home
  2. ARCC vs BBIO Comparison

ARCC vs BBIO Comparison

Compare ARCC & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Capital Corporation

ARCC

Ares Capital Corporation

HOLD

Current Price

$18.84

Market Cap

13.6B

Sector

Finance

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$82.10

Market Cap

15.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARCC
BBIO
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
15.9B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
ARCC
BBIO
Price
$18.84
$82.10
Analyst Decision
Buy
Strong Buy
Analyst Count
11
25
Target Price
$21.36
$86.33
AVG Volume (30 Days)
4.4M
3.2M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
10.28%
N/A
EPS Growth
N/A
N/A
EPS
0.13
N/A
Revenue
N/A
$502,076,000.00
Revenue This Year
$5.77
$89.45
Revenue Next Year
$2.29
$73.78
P/E Ratio
$143.92
N/A
Revenue Growth
N/A
126.26
52 Week Low
$17.40
$42.09
52 Week High
$22.76
$93.42

Technical Indicators

Market Signals
Indicator
ARCC
BBIO
Relative Strength Index (RSI) 49.08 60.60
Support Level $18.37 $62.39
Resistance Level $19.35 $84.85
Average True Range (ATR) 0.29 2.88
MACD 0.00 -0.21
Stochastic Oscillator 30.34 37.94

Price Performance

Historical Comparison
ARCC
BBIO

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: